CN1662498A - 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物 - Google Patents

作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物 Download PDF

Info

Publication number
CN1662498A
CN1662498A CN038138875A CN03813887A CN1662498A CN 1662498 A CN1662498 A CN 1662498A CN 038138875 A CN038138875 A CN 038138875A CN 03813887 A CN03813887 A CN 03813887A CN 1662498 A CN1662498 A CN 1662498A
Authority
CN
China
Prior art keywords
phenyl
tetrahydropyridine
carboxylic acid
chloro
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038138875A
Other languages
English (en)
Chinese (zh)
Inventor
奥利维尔·贝曾康
丹尼尔·比尔
瓦尔特·菲施利
尤博斯·雷门
西尔维娅·理查德-比洛斯泰恩
托马斯·韦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1662498A publication Critical patent/CN1662498A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN038138875A 2002-06-27 2003-04-29 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物 Pending CN1662498A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP02/07102 2002-06-27
EP0207102 2002-06-27

Publications (1)

Publication Number Publication Date
CN1662498A true CN1662498A (zh) 2005-08-31

Family

ID=29797098

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038138875A Pending CN1662498A (zh) 2002-06-27 2003-04-29 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物

Country Status (16)

Country Link
US (1) US20060009497A1 (enExample)
EP (1) EP1519920A1 (enExample)
JP (1) JP2005532371A (enExample)
CN (1) CN1662498A (enExample)
AU (1) AU2003229746A1 (enExample)
BR (1) BR0312000A (enExample)
CA (1) CA2490138A1 (enExample)
CL (1) CL2003002043A1 (enExample)
IL (1) IL165887A0 (enExample)
MX (1) MXPA04012136A (enExample)
NO (1) NO20050290L (enExample)
PL (1) PL375214A1 (enExample)
RU (1) RU2005102002A (enExample)
TW (1) TW200514772A (enExample)
WO (1) WO2004002957A1 (enExample)
ZA (1) ZA200408423B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217371A1 (en) * 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
BRPI0409881A (pt) * 2003-04-29 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
AU2004233575A1 (en) * 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo'3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
RU2005137571A (ru) * 2003-05-02 2006-05-10 Актелион Фармасьютикалз Лтд. (Ch) Новые производные диазабициклононена
WO2004105738A2 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Use of tetrahydropyridine derivatives
CN1863773A (zh) * 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
US20070142363A1 (en) * 2003-10-13 2007-06-21 Actelion Pharmaceuticals Ltd Novel diazabicyclonene derivatives and use thereof
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
CA2552965A1 (en) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Carboxamide derivative and use thereof
NZ586285A (en) * 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
JP2008510755A (ja) 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
GB0428526D0 (en) * 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
KR100963455B1 (ko) * 2005-05-27 2010-06-18 액테리온 파마슈티칼 리미티드 신규한 피페리딘 카르복실산 아미드 유도체
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007049224A1 (en) * 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
JP2009526767A (ja) 2006-02-02 2009-07-23 アクテリオン ファーマシューティカルズ リミテッド 新規二級アミン
AU2007220149A1 (en) * 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors
TW200800897A (en) * 2006-03-08 2008-01-01 Actelion Pharmaceuticals Ltd New amines
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP2162436A4 (en) 2007-05-24 2010-08-04 Merck Frosst Canada Ltd NEW CASE OF RENININHIBITORS
CA2696689A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
CN102015682B (zh) 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
CN117865941B (zh) * 2024-03-13 2024-06-28 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
CA2490138A1 (en) 2004-01-08
MXPA04012136A (es) 2005-04-19
TW200514772A (en) 2005-05-01
AU2003229746A1 (en) 2004-01-19
PL375214A1 (en) 2005-11-28
ZA200408423B (en) 2005-10-11
NO20050290L (no) 2005-01-19
US20060009497A1 (en) 2006-01-12
EP1519920A1 (en) 2005-04-06
WO2004002957A1 (en) 2004-01-08
RU2005102002A (ru) 2005-09-20
JP2005532371A (ja) 2005-10-27
BR0312000A (pt) 2005-03-22
CL2003002043A1 (es) 2005-01-28
IL165887A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
CN1662498A (zh) 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物
CN1158258C (zh) 肾上腺素能α1B受体拮抗药
CN1229349C (zh) 吡啶－3－羧酸衍生物
CN1024547C (zh) 一类环胺化合物的制备方法
CN1046721C (zh) 杂环化合物及其制备方法和用途
CN1257891C (zh) 含氮五员环化合物
CN1281604C (zh) 取代吡唑化合物
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1034364A (zh) 取代吡啶和其制备方法
CN1088207A (zh) 嘧啶化合物
CN1057262A (zh) 环酰胺衍生物
CN1657523A (zh) 环状化合物
CN1279672A (zh) 新颖的哒嗪衍生物和含有其作为有效成分的药物
CN1549817A (zh) 作为半胱氨酸蛋白酶抑制剂的吡咯并嘧啶化合物
CN1227553A (zh) 双环嘧啶衍生物以及其作为抗凝血剂的用途
HK1048311A1 (en) Compounds, their use and preparation
CN1040795A (zh) 三唑类抗霉菌剂的制备方法
CN1382143A (zh) αLβ2介导细胞粘连抑制剂
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2－氨基吡啶
CN1921847A (zh) 氨基醇化合物
CN1211232A (zh) 用氨基酸和羟基酸衍生物取代的苄脒衍生物和其作为抗凝血剂的用途
CN1210265C (zh) 酞嗪衍生物和勃起障碍的治疗剂
CN1507435A (zh) 新型氰基取代的二氢嘧啶化合物及其治疗疾病的用途
CN1040791A (zh) 镇痛羧酸酰胺衍生物
CN1098103A (zh) 新型吡啶酮羧酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication